Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521), a China-based pharmaceutical company, has announced the receipt of Abbreviated New Drug Application (ANDA) approval from the US FDA for its generic version of Japan firm Takeda’s (TYO: 4502) Vyvanse (lisdexamfetamine). Vyvanse is a medication used to treat attention-deficit hyperactivity disorder (ADHD).
Lisdexamfetamine’s Market Entry and Sales Performance
Lisdexamfetamine was first approved in the US in March 2007. With Takeda’s patent expiring on August 24, 2023, Huahai is now cleared to launch its generic version into the US market. The product achieved significant sales in the country last year, generating USD 4.66 billion.
Implications for the ADHD Treatment Market
The ANDA approval for Huahai’s generic Vyvanse is a significant development for the ADHD treatment market. It not only expands patient access to affordable treatment options but also increases competition, potentially driving down costs and improving affordability for consumers.-Fineline Info & Tech
